
Vivian C. Chin
Supervisory Patent Examiner (ID: 17044, Phone: (571)272-7848 , Office: P/2654 )
| Most Active Art Unit | 2747 |
| Art Unit(s) | 2654, 2644, 2695, 2605, 2747, 2608, 2743, 2615, 2614, 2609, 2682 |
| Total Applications | 608 |
| Issued Applications | 319 |
| Pending Applications | 136 |
| Abandoned Applications | 157 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18754011
[patent_doc_number] => 20230357374
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/048386
[patent_app_country] => US
[patent_app_date] => 2022-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18631
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048386
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048386 | THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS | Oct 19, 2022 | Pending |
Array
(
[id] => 19479463
[patent_doc_number] => 20240327505
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => ANTIBODIES TO CORONAVIRUS SARS-COV-2
[patent_app_type] => utility
[patent_app_number] => 18/703646
[patent_app_country] => US
[patent_app_date] => 2022-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28269
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18703646
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/703646 | ANTIBODIES TO CORONAVIRUS SARS-COV-2 | Oct 19, 2022 | Pending |
Array
(
[id] => 18295523
[patent_doc_number] => 20230105209
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/937744
[patent_app_country] => US
[patent_app_date] => 2022-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9421
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937744
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/937744 | Antibody specific to spike protein of SARS-CoV-2 and uses thereof | Oct 2, 2022 | Issued |
Array
(
[id] => 19731131
[patent_doc_number] => 12209122
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-28
[patent_title] => Anti-TNF-alpha-antibodies and functional fragments thereof
[patent_app_type] => utility
[patent_app_number] => 17/958759
[patent_app_country] => US
[patent_app_date] => 2022-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 18
[patent_no_of_words] => 26116
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17958759
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/958759 | Anti-TNF-alpha-antibodies and functional fragments thereof | Oct 2, 2022 | Issued |
Array
(
[id] => 18932304
[patent_doc_number] => 11884711
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-30
[patent_title] => Fusion proteins of GDF15 and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/935134
[patent_app_country] => US
[patent_app_date] => 2022-09-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 11
[patent_no_of_words] => 17547
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935134
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/935134 | Fusion proteins of GDF15 and use thereof | Sep 25, 2022 | Issued |
Array
(
[id] => 18582912
[patent_doc_number] => 20230265169
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => MONOCLONAL ANTIBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/952308
[patent_app_country] => US
[patent_app_date] => 2022-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11809
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 167
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17952308
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/952308 | Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof | Sep 24, 2022 | Issued |
Array
(
[id] => 18468893
[patent_doc_number] => 20230203176
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => Methods For Prevention Of Graft Rejection In Xenotransplantation
[patent_app_type] => utility
[patent_app_number] => 17/946917
[patent_app_country] => US
[patent_app_date] => 2022-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38821
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17946917
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/946917 | Methods For Prevention Of Graft Rejection In Xenotransplantation | Sep 15, 2022 | Abandoned |
Array
(
[id] => 20077597
[patent_doc_number] => 12351647
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-08
[patent_title] => Binding agent and assay for PIVKA
[patent_app_type] => utility
[patent_app_number] => 17/821937
[patent_app_country] => US
[patent_app_date] => 2022-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 15710
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 242
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821937
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/821937 | Binding agent and assay for PIVKA | Aug 23, 2022 | Issued |
Array
(
[id] => 18597264
[patent_doc_number] => 20230272059
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/890857
[patent_app_country] => US
[patent_app_date] => 2022-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26143
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 348
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17890857
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/890857 | Anti-TNF-alpha-antibodies and functional fragments thereof | Aug 17, 2022 | Issued |
Array
(
[id] => 18141449
[patent_doc_number] => 20230015291
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => DNASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/819006
[patent_app_country] => US
[patent_app_date] => 2022-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51959
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17819006
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/819006 | DNASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | Aug 10, 2022 | Abandoned |
Array
(
[id] => 19738349
[patent_doc_number] => 12215167
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-04
[patent_title] => Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
[patent_app_type] => utility
[patent_app_number] => 17/877853
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 47
[patent_figures_cnt] => 88
[patent_no_of_words] => 107500
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17877853
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/877853 | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods | Jul 28, 2022 | Issued |
Array
(
[id] => 19731132
[patent_doc_number] => 12209123
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-28
[patent_title] => Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
[patent_app_type] => utility
[patent_app_number] => 17/814075
[patent_app_country] => US
[patent_app_date] => 2022-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 68
[patent_no_of_words] => 26148
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814075
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/814075 | Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases | Jul 20, 2022 | Issued |
Array
(
[id] => 18228932
[patent_doc_number] => 20230067926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => SYSTEMS AND METHODS FOR MONITORING PLATELET ACTIVATION
[patent_app_type] => utility
[patent_app_number] => 17/868422
[patent_app_country] => US
[patent_app_date] => 2022-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5996
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17868422
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/868422 | SYSTEMS AND METHODS FOR MONITORING PLATELET ACTIVATION | Jul 18, 2022 | Pending |
Array
(
[id] => 18077402
[patent_doc_number] => 20220403014
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => COMPOSITIONS AND METHODS OF TREATING THROMBOSIS
[patent_app_type] => utility
[patent_app_number] => 17/846697
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18925
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846697
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/846697 | COMPOSITIONS AND METHODS OF TREATING THROMBOSIS | Jun 21, 2022 | Abandoned |
Array
(
[id] => 18141339
[patent_doc_number] => 20230015181
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/843777
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46513
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843777
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/843777 | Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof | Jun 16, 2022 | Pending |
Array
(
[id] => 18207374
[patent_doc_number] => 20230053631
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => ANTIBODIES TO LILRB2
[patent_app_type] => utility
[patent_app_number] => 17/838426
[patent_app_country] => US
[patent_app_date] => 2022-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49402
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17838426
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/838426 | ANTIBODIES TO LILRB2 | Jun 12, 2022 | Abandoned |
Array
(
[id] => 17990198
[patent_doc_number] => 20220356235
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/829688
[patent_app_country] => US
[patent_app_date] => 2022-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21917
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829688
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/829688 | FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF | May 31, 2022 | Pending |
Array
(
[id] => 18125821
[patent_doc_number] => 20230011438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-12
[patent_title] => CHIMERIC FACTOR VIII POLYPEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/826932
[patent_app_country] => US
[patent_app_date] => 2022-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61044
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17826932
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/826932 | CHIMERIC FACTOR VIII POLYPEPTIDES AND USES THEREOF | May 26, 2022 | Pending |
Array
(
[id] => 18094655
[patent_doc_number] => 20220412996
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => BLOOD FACTOR MONITORING ASSAY AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/749834
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30765
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749834
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/749834 | BLOOD FACTOR MONITORING ASSAY AND USES THEREOF | May 19, 2022 | Pending |
Array
(
[id] => 19692902
[patent_doc_number] => 20250011447
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => BISPECIFIC ANTIBODY BINDING TO BCMA AND CD3, AND PREPARATION METHOD THEREFOR AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/256316
[patent_app_country] => US
[patent_app_date] => 2022-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12589
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256316
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/256316 | BISPECIFIC ANTIBODY BINDING TO BCMA AND CD3, AND PREPARATION METHOD THEREFOR AND USE THEREOF | May 4, 2022 | Pending |